These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 26859714)

  • 1. A current pharmacologic agent versus the promise of next generation therapeutics to ameliorate protein misfolding and/or aggregation diseases.
    Baranczak A; Kelly JW
    Curr Opin Chem Biol; 2016 Jun; 32():10-21. PubMed ID: 26859714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Underlying mechanisms and chemical/biochemical therapeutic approaches to ameliorate protein misfolding neurodegenerative diseases.
    Hekmatimoghaddam S; Zare-Khormizi MR; Pourrajab F
    Biofactors; 2017 Nov; 43(6):737-759. PubMed ID: 26899445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemical and biological approaches for adapting proteostasis to ameliorate protein misfolding and aggregation diseases: progress and prognosis.
    Lindquist SL; Kelly JW
    Cold Spring Harb Perspect Biol; 2011 Dec; 3(12):. PubMed ID: 21900404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protein misfolding in disease and small molecule therapies.
    Gomes CM
    Curr Top Med Chem; 2012; 12(22):2460-9. PubMed ID: 23339300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thermodynamic and kinetic approaches for drug discovery to target protein misfolding and aggregation.
    Vendruscolo M
    Expert Opin Drug Discov; 2023; 18(8):881-891. PubMed ID: 37276120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Camelid single-domain antibody fragments: Uses and prospects to investigate protein misfolding and aggregation, and to treat diseases associated with these phenomena.
    Pain C; Dumont J; Dumoulin M
    Biochimie; 2015 Apr; 111():82-106. PubMed ID: 25656912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent developments in targeting protein misfolding diseases.
    Denny RA; Gavrin LK; Saiah E
    Bioorg Med Chem Lett; 2013 Apr; 23(7):1935-44. PubMed ID: 23454013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemical and/or biological therapeutic strategies to ameliorate protein misfolding diseases.
    Ong DS; Kelly JW
    Curr Opin Cell Biol; 2011 Apr; 23(2):231-8. PubMed ID: 21146391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo aspects of protein folding and quality control.
    Balchin D; Hayer-Hartl M; Hartl FU
    Science; 2016 Jul; 353(6294):aac4354. PubMed ID: 27365453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemical kinetics for drug discovery to combat protein aggregation diseases.
    Arosio P; Vendruscolo M; Dobson CM; Knowles TP
    Trends Pharmacol Sci; 2014 Mar; 35(3):127-35. PubMed ID: 24560688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Using pharmacological chaperones to restore proteostasis.
    Wang YJ; Di XJ; Mu TW
    Pharmacol Res; 2014 May; 83():3-9. PubMed ID: 24747662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protein folding, misfolding, aggregation and their implications in human diseases: discovering therapeutic ways to amyloid-associated diseases.
    Iram A; Naeem A
    Cell Biochem Biophys; 2014 Sep; 70(1):51-61. PubMed ID: 24639112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular chaperone functions in protein folding and proteostasis.
    Kim YE; Hipp MS; Bracher A; Hayer-Hartl M; Hartl FU
    Annu Rev Biochem; 2013; 82():323-55. PubMed ID: 23746257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanochaperone-Based Strategies to Control Protein Aggregation Linked to Conformational Diseases.
    Caballero AB; Gamez P
    Angew Chem Int Ed Engl; 2021 Jan; 60(1):41-52. PubMed ID: 32706460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular pathways to polyglutamine aggregation.
    Robertson AL; Bottomley SP
    Adv Exp Med Biol; 2012; 769():115-24. PubMed ID: 23560307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibiting toxic aggregation of amyloidogenic proteins: a therapeutic strategy for protein misfolding diseases.
    Cheng B; Gong H; Xiao H; Petersen RB; Zheng L; Huang K
    Biochim Biophys Acta; 2013 Oct; 1830(10):4860-71. PubMed ID: 23820032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteostasis impairment in protein-misfolding and -aggregation diseases.
    Hipp MS; Park SH; Hartl FU
    Trends Cell Biol; 2014 Sep; 24(9):506-14. PubMed ID: 24946960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Small molecules that target protein misfolding.
    Gavrin LK; Denny RA; Saiah E
    J Med Chem; 2012 Dec; 55(24):10823-43. PubMed ID: 23075044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacoperones: targeting therapeutics toward diseases caused by protein misfolding.
    Ulloa-Aguirre A; Zariñán T; Conn PM
    Rev Invest Clin; 2015; 67(1):15-9. PubMed ID: 25857579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protein misfolding and related human diseases: A comprehensive review of toxicity, proteins involved, and current therapeutic strategies.
    Khan AN; Khan RH
    Int J Biol Macromol; 2022 Dec; 223(Pt A):143-160. PubMed ID: 36356861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.